LLY · News · 20260922N
Manufacturing and Capital Expenditure Program
ELI LILLY & Co · 2026-09-22 · Importance 52 · Surprise 42 · In source text
Eli Lilly is expanding manufacturing capacity for the oral obesity treatment Foundayo. The company is building a Houston facility costing $6.5 billion to produce Foundayo’s active ingredient. The facility is targeted to begin operations by 2030, while Lilly also plans to introduce Foundayo in additional international markets.
Key facts
- Eli Lilly is building a new $6.5 billion facility in Houston to produce Foundayo's active ingredient. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | committed | +3.9% | Eli Lilly is building a new $6.5 billion facility in Houston to produce Foundayo's active ingredient. |
| cash | negative | committed | -3.9% | Eli Lilly is building a new $6.5 billion facility in Houston to produce Foundayo's active ingredient. |